{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:09:50Z","timestamp":1793736590559,"version":"4.6.1"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-024-02539-x","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T13:40:19Z","timestamp":1734615619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives"],"prefix":"10.1186","volume":"23","author":[{"given":"Cassandra","family":"Morciano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Gugliandolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Capece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Di Giuseppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Mezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gea","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Soldovieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Splendore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giaccari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"2539_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, et al. Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720. Empagliflozin.","journal-title":"N Engl J Med"},{"key":"2539_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","volume":"137","author":"KW Mahaffey","year":"2018","unstructured":"Mahaffey KW, et al. Canagliflozin for primary and Secondary Prevention of Cardiovascular Events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137:323\u201334. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032038.","journal-title":"Circulation"},{"key":"2539_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, et al. Dapagliflozin and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"key":"2539_CR4","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"key":"2539_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","volume":"19","author":"L Ni","year":"2020","unstructured":"Ni L, Yuan C, Chen G, Zhang C, Wu X. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020;19:98. https:\/\/doi.org\/10.1186\/s12933-020-01071-y.","journal-title":"Cardiovasc Diabetol"},{"key":"2539_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","volume":"20","author":"KM Hallow","year":"2018","unstructured":"Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018;20:479\u201387. https:\/\/doi.org\/10.1111\/dom.13126.","journal-title":"Diabetes Obes Metab"},{"key":"2539_CR7","doi-asserted-by":"publisher","first-page":"104536","DOI":"10.1016\/j.amsu.2022.104536","volume":"81","author":"A Zaawari","year":"2022","unstructured":"Zaawari A, Sahar AN. Sodium-glucose co-transporter-2 inhibitors (SGLT2I): a class of drugs with promising cardiorenal protective effects beyond glycemic control. Ann Med Surg (Lond). 2022;81:104536. https:\/\/doi.org\/10.1016\/j.amsu.2022.104536.","journal-title":"Ann Med Surg (Lond)"},{"key":"2539_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12933-022-01607-4","volume":"21","author":"L Leccisotti","year":"2022","unstructured":"Leccisotti L, et al. Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report. Cardiovasc Diabetol. 2022;21:173. https:\/\/doi.org\/10.1186\/s12933-022-01607-4.","journal-title":"Cardiovasc Diabetol"},{"key":"2539_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12933-023-02091-0","volume":"22","author":"F Cinti","year":"2023","unstructured":"Cinti F, et al. Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes. Cardiovasc Diabetol. 2023;22:349. https:\/\/doi.org\/10.1186\/s12933-023-02091-0.","journal-title":"Cardiovasc Diabetol"},{"key":"2539_CR10","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1007\/s13300-021-01083-1","volume":"12","author":"GP Sorice","year":"2021","unstructured":"Sorice GP, et al. Effect of Dapagliflozin on myocardial insulin sensitivity and perfusion: Rationale and Design of the DAPAHEART Trial. Diabetes Ther. 2021;12:2101\u201313. https:\/\/doi.org\/10.1007\/s13300-021-01083-1.","journal-title":"Diabetes Ther"},{"key":"2539_CR11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2459\/JCM.0000000000001453","volume":"24","author":"L Li","year":"2023","unstructured":"Li L, et al. SGLT2i alleviates epicardial adipose tissue inflammation by modulating ketone body-glyceraldehyde-3-phosphate dehydrogenase malonylation pathway. J Cardiovasc Med (Hagerstown). 2023;24:232\u201343. https:\/\/doi.org\/10.2459\/JCM.0000000000001453.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2539_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature21363","volume":"542","author":"GS Hotamisligil","year":"2017","unstructured":"Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542:177\u201385. https:\/\/doi.org\/10.1038\/nature21363.","journal-title":"Nature"},{"key":"2539_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0140-6736(24)00003-5","volume":"403","author":"L The","year":"2024","unstructured":"The L. Treating obesity and diabetes: drugs alone are not enough. Lancet. 2024;403:1. https:\/\/doi.org\/10.1016\/S0140-6736(24)00003-5.","journal-title":"Lancet"},{"key":"2539_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-024-01473-y","author":"E Melson","year":"2024","unstructured":"Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2024. https:\/\/doi.org\/10.1038\/s41366-024-01473-y.","journal-title":"Int J Obes (Lond)"},{"key":"2539_CR15","doi-asserted-by":"publisher","first-page":"102181","DOI":"10.1016\/j.eclinm.2023.102181","volume":"64","author":"I Caruso","year":"2023","unstructured":"Caruso I, et al. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. EClinicalMedicine. 2023;64:102181. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102181.","journal-title":"EClinicalMedicine"},{"key":"2539_CR16","unstructured":"Padda IS, Mahtani AU, Parmar M. in StatPearls (2024)."},{"key":"2539_CR17","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1517\/13543776.2015.1076392","volume":"25","author":"M Jiang","year":"2015","unstructured":"Jiang M, Steyger PS. An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus. Expert Opin Ther Pat. 2015;25:1349\u201352. https:\/\/doi.org\/10.1517\/13543776.2015.1076392.","journal-title":"Expert Opin Ther Pat"},{"key":"2539_CR18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12933-021-01430-3","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano D, et al. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc Diabetol. 2021;20:236. https:\/\/doi.org\/10.1186\/s12933-021-01430-3.","journal-title":"Cardiovasc Diabetol"},{"key":"2539_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12933-022-01575-9","volume":"21","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, et al. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovasc Diabetol. 2022;21:144. https:\/\/doi.org\/10.1186\/s12933-022-01575-9.","journal-title":"Cardiovasc Diabetol"},{"key":"2539_CR20","doi-asserted-by":"publisher","first-page":"e245135","DOI":"10.1001\/jamanetworkopen.2024.5135","volume":"7","author":"M Gao","year":"2024","unstructured":"Gao M, et al. SGLT2 inhibitors, functional capacity, and quality of life in patients with heart failure: a systematic review and Meta-analysis. JAMA Netw Open. 2024;7:e245135. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.5135.","journal-title":"JAMA Netw Open"},{"key":"2539_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpae092","author":"V Vallon","year":"2024","unstructured":"Vallon V. State-of-the-art-review mechanisms of action of SGLT2 inhibitors and clinical implications. Am J Hypertens. 2024. https:\/\/doi.org\/10.1093\/ajh\/hpae092.","journal-title":"Am J Hypertens"},{"key":"2539_CR22","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2337\/dc15-0355","volume":"38","author":"G Ferrannini","year":"2015","unstructured":"Ferrannini G, et al. Energy Balance after Sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1730\u20135. https:\/\/doi.org\/10.2337\/dc15-0355.","journal-title":"Diabetes Care"},{"key":"2539_CR23","doi-asserted-by":"publisher","unstructured":"Giordano A, et al. The adipose organ is a Unitary structure in mice and humans. Biomedicines. 2022;10. https:\/\/doi.org\/10.3390\/biomedicines10092275.","DOI":"10.3390\/biomedicines10092275"},{"key":"2539_CR24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.tem.2018.05.007","volume":"29","author":"S Cinti","year":"2018","unstructured":"Cinti S. Pink adipocytes. Trends Endocrinol Metab. 2018;29:651\u201366. https:\/\/doi.org\/10.1016\/j.tem.2018.05.007.","journal-title":"Trends Endocrinol Metab"},{"key":"2539_CR25","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/cphy.c170042","volume":"8","author":"S Cinti","year":"2018","unstructured":"Cinti S. Adipose Organ Development and Remodeling. Compr Physiol. 2018;8:1357\u2013431. https:\/\/doi.org\/10.1002\/cphy.c170042.","journal-title":"Compr Physiol"},{"key":"2539_CR26","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/372425a0","volume":"372","author":"Y Zhang","year":"1994","unstructured":"Zhang Y, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425\u201332. https:\/\/doi.org\/10.1038\/372425a0.","journal-title":"Nature"},{"key":"2539_CR27","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/nm.4432","volume":"23","author":"C Duerrschmid","year":"2017","unstructured":"Duerrschmid C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017;23:1444\u201353. https:\/\/doi.org\/10.1038\/nm.4432.","journal-title":"Nat Med"},{"key":"2539_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1369\/jhc.6A7013.2006","volume":"55","author":"A Frontini","year":"2007","unstructured":"Frontini A, et al. Thymus uncoupling protein 1 is exclusive to typical brown adipocytes and is not found in thymocytes. J Histochem Cytochem. 2007;55:183\u20139. https:\/\/doi.org\/10.1369\/jhc.6A7013.2006.","journal-title":"J Histochem Cytochem"},{"key":"2539_CR29","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1152\/physrev.00015.2003","volume":"84","author":"B Cannon","year":"2004","unstructured":"Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004;84:277\u2013359. https:\/\/doi.org\/10.1152\/physrev.00015.2003.","journal-title":"Physiol Rev"},{"key":"2539_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/164_2015_6","volume":"233","author":"M Giralt","year":"2016","unstructured":"Giralt M, Cereijo R, Villarroya F. Adipokines and the endocrine role of adipose tissues. Handb Exp Pharmacol. 2016;233:265\u201382. https:\/\/doi.org\/10.1007\/164_2015_6.","journal-title":"Handb Exp Pharmacol"},{"key":"2539_CR31","doi-asserted-by":"publisher","first-page":"E1244","DOI":"10.1152\/ajpendo.00600.2009","volume":"298","author":"G Barbatelli","year":"2010","unstructured":"Barbatelli G, et al. The emergence of cold-induced brown adipocytes in mouse white fat depots is determined predominantly by white to brown adipocyte transdifferentiation. Am J Physiol Endocrinol Metab. 2010;298:E1244\u20131253. https:\/\/doi.org\/10.1152\/ajpendo.00600.2009.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2539_CR32","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.bbalip.2013.02.005","volume":"1831","author":"A Frontini","year":"2013","unstructured":"Frontini A, et al. White-to-brown transdifferentiation of omental adipocytes in patients affected by pheochromocytoma. Biochim Biophys Acta. 2013;1831:950\u20139. https:\/\/doi.org\/10.1016\/j.bbalip.2013.02.005.","journal-title":"Biochim Biophys Acta"},{"key":"2539_CR33","doi-asserted-by":"publisher","unstructured":"Ronkainen J, et al. Fto-Deficiency affects the gene and MicroRNA expression involved in Brown Adipogenesis and Browning of White Adipose tissue in mice. Int J Mol Sci. 2016;17. https:\/\/doi.org\/10.3390\/ijms17111851.","DOI":"10.3390\/ijms17111851"},{"key":"2539_CR34","doi-asserted-by":"publisher","unstructured":"Osataphan S, et al. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms. JCI Insight. 2019;4. https:\/\/doi.org\/10.1172\/jci.insight.123130.","DOI":"10.1172\/jci.insight.123130"},{"key":"2539_CR35","doi-asserted-by":"publisher","first-page":"E1448","DOI":"10.1210\/jc.2013-1265","volume":"98","author":"HS Sacks","year":"2013","unstructured":"Sacks HS, et al. Adult epicardial fat exhibits beige features. J Clin Endocrinol Metab. 2013;98:E1448\u20131455. https:\/\/doi.org\/10.1210\/jc.2013-1265.","journal-title":"J Clin Endocrinol Metab"},{"key":"2539_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cell.2013.12.012","volume":"156","author":"ED Rosen","year":"2014","unstructured":"Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell. 2014;156:20\u201344. https:\/\/doi.org\/10.1016\/j.cell.2013.12.012.","journal-title":"Cell"},{"key":"2539_CR37","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1074\/jbc.M006246200","volume":"276","author":"MJ Barbera","year":"2001","unstructured":"Barbera MJ, et al. Peroxisome proliferator-activated receptor alpha activates transcription of the brown fat uncoupling protein-1 gene. A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell. J Biol Chem. 2001;276:1486\u201393. https:\/\/doi.org\/10.1074\/jbc.M006246200.","journal-title":"J Biol Chem"},{"key":"2539_CR38","doi-asserted-by":"publisher","first-page":"R159","DOI":"10.1530\/EJE-13-0945","volume":"170","author":"A Giordano","year":"2014","unstructured":"Giordano A, Smorlesi A, Frontini A, Barbatelli G, Cinti S. White, brown and pink adipocytes: the extraordinary plasticity of the adipose organ. Eur J Endocrinol. 2014;170:R159\u2013171. https:\/\/doi.org\/10.1530\/EJE-13-0945.","journal-title":"Eur J Endocrinol"},{"key":"2539_CR39","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.numecd.2012.01.013","volume":"23","author":"R De Matteis","year":"2013","unstructured":"De Matteis R, et al. Exercise as a new physiological stimulus for brown adipose tissue activity. Nutr Metab Cardiovasc Dis. 2013;23:582\u201390. https:\/\/doi.org\/10.1016\/j.numecd.2012.01.013.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2539_CR40","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nature10777","volume":"481","author":"P Bostrom","year":"2012","unstructured":"Bostrom P, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463\u20138. https:\/\/doi.org\/10.1038\/nature10777.","journal-title":"Nature"},{"key":"2539_CR41","doi-asserted-by":"publisher","first-page":"9233","DOI":"10.1038\/srep09233","volume":"5","author":"J Ronkainen","year":"2015","unstructured":"Ronkainen J, et al. Fat mass- and obesity-associated gene fto affects the dietary response in mouse white adipose tissue. Sci Rep. 2015;5:9233. https:\/\/doi.org\/10.1038\/srep09233.","journal-title":"Sci Rep"},{"key":"2539_CR42","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/164_2018_159","volume":"251","author":"T Yoneshiro","year":"2019","unstructured":"Yoneshiro T, Matsushita M, Saito M. Translational aspects of Brown Fat activation by Food-Derived stimulants. Handb Exp Pharmacol. 2019;251:359\u201379. https:\/\/doi.org\/10.1007\/164_2018_159.","journal-title":"Handb Exp Pharmacol"},{"key":"2539_CR43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cmet.2014.12.009","volume":"21","author":"AM Cypess","year":"2015","unstructured":"Cypess AM, et al. Activation of human brown adipose tissue by a beta3-adrenergic receptor agonist. Cell Metab. 2015;21:33\u20138. https:\/\/doi.org\/10.1016\/j.cmet.2014.12.009.","journal-title":"Cell Metab"},{"key":"2539_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11154-021-09640-6","volume":"23","author":"A Gavalda-Navarro","year":"2022","unstructured":"Gavalda-Navarro A, Villarroya J, Cereijo R, Giralt M, Villarroya F. The endocrine role of brown adipose tissue: an update on actors and actions. Rev Endocr Metab Disord. 2022;23:31\u201341. https:\/\/doi.org\/10.1007\/s11154-021-09640-6.","journal-title":"Rev Endocr Metab Disord"},{"key":"2539_CR45","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1096\/fj.13-245415","volume":"28","author":"A Armani","year":"2014","unstructured":"Armani A, et al. Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice. FASEB J. 2014;28:3745\u201357. https:\/\/doi.org\/10.1096\/fj.13-245415.","journal-title":"FASEB J"},{"key":"2539_CR46","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.mce.2011.09.011","volume":"350","author":"V Marzolla","year":"2012","unstructured":"Marzolla V, et al. The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism. Mol Cell Endocrinol. 2012;350:281\u20138. https:\/\/doi.org\/10.1016\/j.mce.2011.09.011.","journal-title":"Mol Cell Endocrinol"},{"key":"2539_CR47","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/ijo.2016.13","volume":"40","author":"C Mammi","year":"2016","unstructured":"Mammi C, et al. A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet. Int J Obes (Lond). 2016;40:964\u201372. https:\/\/doi.org\/10.1038\/ijo.2016.13.","journal-title":"Int J Obes (Lond)"},{"key":"2539_CR48","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3389\/fendo.2015.00148","volume":"6","author":"B Ni","year":"2015","unstructured":"Ni B, Farrar JS, Vaitkus JA, Celi FS. Metabolic effects of FGF-21: Thermoregulation and Beyond. Front Endocrinol (Lausanne). 2015;6:148. https:\/\/doi.org\/10.3389\/fendo.2015.00148.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2539_CR49","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nrd.2016.31","volume":"15","author":"A Giordano","year":"2016","unstructured":"Giordano A, Frontini A, Cinti S. Convertible visceral fat as a therapeutic target to curb obesity. Nat Rev Drug Discov. 2016;15:405\u201324. https:\/\/doi.org\/10.1038\/nrd.2016.31.","journal-title":"Nat Rev Drug Discov"},{"key":"2539_CR50","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/ajcn\/4.1.20","volume":"4","author":"J Vague","year":"1956","unstructured":"Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr. 1956;4:20\u201334. https:\/\/doi.org\/10.1093\/ajcn\/4.1.20.","journal-title":"Am J Clin Nutr"},{"key":"2539_CR51","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3945\/ajcn.116.147157","volume":"106","author":"K Bowman","year":"2017","unstructured":"Bowman K, et al. Central adiposity and the overweight risk paradox in aging: follow-up of 130,473 UK Biobank participants. Am J Clin Nutr. 2017;106:130\u20135. https:\/\/doi.org\/10.3945\/ajcn.116.147157.","journal-title":"Am J Clin Nutr"},{"key":"2539_CR52","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1038\/nutd.2015.22","volume":"5","author":"V Guglielmi","year":"2015","unstructured":"Guglielmi V, et al. Omental adipose tissue fibrosis and insulin resistance in severe obesity. Nutr Diabetes. 2015;5:e175. https:\/\/doi.org\/10.1038\/nutd.2015.22.","journal-title":"Nutr Diabetes"},{"key":"2539_CR53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41569-018-0097-6","volume":"16","author":"EK Oikonomou","year":"2019","unstructured":"Oikonomou EK, Antoniades C. The role of adipose tissue in cardiovascular health and disease. Nat Rev Cardiol. 2019;16:83\u201399. https:\/\/doi.org\/10.1038\/s41569-018-0097-6.","journal-title":"Nat Rev Cardiol"},{"key":"2539_CR54","doi-asserted-by":"publisher","first-page":"973135","DOI":"10.3389\/fcell.2022.973135","volume":"10","author":"I Badi","year":"2022","unstructured":"Badi I, et al. Editorial: exploring the Crosstalk between adipose tissue and the Cardiovascular System. Front Cell Dev Biol. 2022;10:973135. https:\/\/doi.org\/10.3389\/fcell.2022.973135.","journal-title":"Front Cell Dev Biol"},{"key":"2539_CR55","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/cvr\/cvx111","volume":"113","author":"I Akoumianakis","year":"2017","unstructured":"Akoumianakis I, Antoniades C. The interplay between adipose tissue and the cardiovascular system: is fat always bad? Cardiovasc Res. 2017;113:999\u20131008. https:\/\/doi.org\/10.1093\/cvr\/cvx111.","journal-title":"Cardiovasc Res"},{"key":"2539_CR56","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41569-022-00679-9","volume":"19","author":"G Iacobellis","year":"2022","unstructured":"Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19:593\u2013606. https:\/\/doi.org\/10.1038\/s41569-022-00679-9.","journal-title":"Nat Rev Cardiol"},{"key":"2539_CR57","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0305-0491(89)90337-4","volume":"94","author":"JM Marchington","year":"1989","unstructured":"Marchington JM, Mattacks CA, Pond CM. Adipose tissue in the mammalian heart and pericardium: structure, foetal development and biochemical properties. Comp Biochem Physiol B. 1989;94:225\u201332. https:\/\/doi.org\/10.1016\/0305-0491(89)90337-4.","journal-title":"Comp Biochem Physiol B"},{"key":"2539_CR58","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.tem.2011.07.003","volume":"22","author":"G Iacobellis","year":"2011","unstructured":"Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab. 2011;22:450\u20137. https:\/\/doi.org\/10.1016\/j.tem.2011.07.003.","journal-title":"Trends Endocrinol Metab"},{"key":"2539_CR59","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jacc.2023.05.031","volume":"82","author":"MC Carena","year":"2023","unstructured":"Carena MC, et al. Role of human epicardial adipose tissue-derived miR-92a-3p in myocardial redox state. J Am Coll Cardiol. 2023;82:317\u201332. https:\/\/doi.org\/10.1016\/j.jacc.2023.05.031.","journal-title":"J Am Coll Cardiol"},{"key":"2539_CR60","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1161\/CIRCULATIONAHA.120.051981","volume":"143","author":"I Badi","year":"2021","unstructured":"Badi I, Antoniades C. Brown Adipose tissue and the take (12,13-di)HOME Message to the heart. Circulation. 2021;143:160\u20132. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051981.","journal-title":"Circulation"},{"key":"2539_CR61","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/CIRCULATIONAHA.120.049813","volume":"143","author":"KM Pinckard","year":"2021","unstructured":"Pinckard KM, et al. A novel endocrine role for the BAT-Released lipokine 12,13-diHOME to Mediate Cardiac function. Circulation. 2021;143:145\u201359. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.049813.","journal-title":"Circulation"},{"key":"2539_CR62","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1161\/01.CIR.0000099542.57313.C5","volume":"108","author":"T Mazurek","year":"2003","unstructured":"Mazurek T, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003;108:2460\u20136. https:\/\/doi.org\/10.1161\/01.CIR.0000099542.57313.C5.","journal-title":"Circulation"},{"key":"2539_CR63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12933-019-0807-3","volume":"18","author":"Y Li","year":"2019","unstructured":"Li Y, et al. Epicardial fat tissue in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol. 2019;18:3. https:\/\/doi.org\/10.1186\/s12933-019-0807-3.","journal-title":"Cardiovasc Diabetol"},{"key":"2539_CR64","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1007\/s40519-022-01420-8","volume":"27","author":"AE Malavazos","year":"2022","unstructured":"Malavazos AE, et al. The density of crown-like structures in epicardial adipose tissue could play a role in cardiovascular diseases. Eat Weight Disord. 2022;27:2905\u201310. https:\/\/doi.org\/10.1007\/s40519-022-01420-8.","journal-title":"Eat Weight Disord"},{"key":"2539_CR65","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1172\/JCI19246","volume":"112","author":"SP Weisberg","year":"2003","unstructured":"Weisberg SP, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796\u2013808. https:\/\/doi.org\/10.1172\/JCI19246.","journal-title":"J Clin Invest"},{"key":"2539_CR66","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1194\/jlr.M079665","volume":"59","author":"P Kotzbeck","year":"2018","unstructured":"Kotzbeck P, et al. Brown adipose tissue whitening leads to brown adipocyte death and adipose tissue inflammation. J Lipid Res. 2018;59:784\u201394. https:\/\/doi.org\/10.1194\/jlr.M079665.","journal-title":"J Lipid Res"},{"key":"2539_CR67","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/0002-9149(67)90001-x","volume":"20","author":"C Valori","year":"1967","unstructured":"Valori C, Thomas M, Shillingford J. Free noradrenaline and adrenaline excretion in relation to clinical syndromes following myocardial infarction. Am J Cardiol. 1967;20:605\u201317. https:\/\/doi.org\/10.1016\/0002-9149(67)90001-x.","journal-title":"Am J Cardiol"},{"key":"2539_CR68","doi-asserted-by":"publisher","first-page":"1036945","DOI":"10.3389\/fphys.2022.1036945","volume":"13","author":"L Wang","year":"2022","unstructured":"Wang L, et al. Cardiac ischemia modulates white adipose tissue in a depot-specific manner. Front Physiol. 2022;13:1036945. https:\/\/doi.org\/10.3389\/fphys.2022.1036945.","journal-title":"Front Physiol"},{"key":"2539_CR69","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa0810780","volume":"360","author":"AM Cypess","year":"2009","unstructured":"Cypess AM, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009;360:1509\u201317. https:\/\/doi.org\/10.1056\/NEJMoa0810780.","journal-title":"N Engl J Med"},{"key":"2539_CR70","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1161\/CIRCULATIONAHA.111.042929","volume":"125","author":"CS Tam","year":"2012","unstructured":"Tam CS, Lecoultre V, Ravussin E. Brown adipose tissue: mechanisms and potential therapeutic targets. Circulation. 2012;125:2782\u201391. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.042929.","journal-title":"Circulation"},{"key":"2539_CR71","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41591-020-1126-7","volume":"27","author":"T Becher","year":"2021","unstructured":"Becher T, et al. Brown adipose tissue is associated with cardiometabolic health. Nat Med. 2021;27:58\u201365. https:\/\/doi.org\/10.1038\/s41591-020-1126-7.","journal-title":"Nat Med"},{"key":"2539_CR72","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41569-023-00847-5","volume":"20","author":"PL Valenzuela","year":"2023","unstructured":"Valenzuela PL, et al. Obesity and the risk of cardiometabolic diseases. Nat Rev Cardiol. 2023;20:475\u201394. https:\/\/doi.org\/10.1038\/s41569-023-00847-5.","journal-title":"Nat Rev Cardiol"},{"key":"2539_CR73","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad484","author":"C Antoniades","year":"2023","unstructured":"Antoniades C, et al. Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers. Eur Heart J. 2023. https:\/\/doi.org\/10.1093\/eurheartj\/ehad484.","journal-title":"Eur Heart J"},{"key":"2539_CR74","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40618-021-01687-1","volume":"45","author":"G Iacobellis","year":"2022","unstructured":"Iacobellis G, Baroni MG. Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat. J Endocrinol Invest. 2022;45:489\u201395. https:\/\/doi.org\/10.1007\/s40618-021-01687-1.","journal-title":"J Endocrinol Invest"},{"key":"2539_CR75","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01491-5","author":"U Capece","year":"2023","unstructured":"Capece U, et al. Dapagliflozin-Induced myocardial Flow Reserve Improvement is not Associated with HDL ability to stimulate endothelial nitric oxide production. Diabetes Ther. 2023. https:\/\/doi.org\/10.1007\/s13300-023-01491-5.","journal-title":"Diabetes Ther"},{"key":"2539_CR76","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73:1931\u201344. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.056.","journal-title":"J Am Coll Cardiol"},{"key":"2539_CR77","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1161\/CIRCULATIONAHA.122.060805","volume":"146","author":"CG Santos-Gallego","year":"2022","unstructured":"Santos-Gallego CG, Mayr M, Badimon J. SGLT2 inhibitors in Heart failure: targeted metabolomics and energetic metabolism. Circulation. 2022;146:819\u201321. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.060805.","journal-title":"Circulation"},{"key":"2539_CR78","doi-asserted-by":"publisher","first-page":"8805","DOI":"10.1038\/s41598-018-27181-y","volume":"8","author":"S Nishitani","year":"2018","unstructured":"Nishitani S, et al. Metabolomic and microarray analyses of adipose tissue of dapagliflozin-treated mice, and effects of 3-hydroxybutyrate on induction of adiponectin in adipocytes. Sci Rep. 2018;8:8805. https:\/\/doi.org\/10.1038\/s41598-018-27181-y.","journal-title":"Sci Rep"},{"key":"2539_CR79","doi-asserted-by":"publisher","unstructured":"Youssef ME, et al. Unlocking the full potential of SGLT2 inhibitors: expanding applications beyond Glycemic Control. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms24076039.","DOI":"10.3390\/ijms24076039"},{"key":"2539_CR80","doi-asserted-by":"publisher","first-page":"16113","DOI":"10.1038\/s41598-018-34305-x","volume":"8","author":"Y Miyachi","year":"2018","unstructured":"Miyachi Y, et al. A reduced M1-like\/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition. Sci Rep. 2018;8:16113. https:\/\/doi.org\/10.1038\/s41598-018-34305-x.","journal-title":"Sci Rep"},{"key":"2539_CR81","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cmet.2015.06.004","volume":"22","author":"X Hui","year":"2015","unstructured":"Hui X, et al. Adiponectin enhances Cold-Induced Browning of Subcutaneous Adipose tissue via promoting M2 macrophage proliferation. Cell Metab. 2015;22:279\u201390. https:\/\/doi.org\/10.1016\/j.cmet.2015.06.004.","journal-title":"Cell Metab"},{"key":"2539_CR82","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13293-022-00455-x","volume":"13","author":"JE Pruett","year":"2022","unstructured":"Pruett JE, et al. Mitochondrial function and oxidative stress in white adipose tissue in a rat model of PCOS: effect of SGLT2 inhibition. Biol Sex Differ. 2022;13:45. https:\/\/doi.org\/10.1186\/s13293-022-00455-x.","journal-title":"Biol Sex Differ"},{"key":"2539_CR83","doi-asserted-by":"publisher","first-page":"e019995","DOI":"10.1161\/JAHA.120.019995","volume":"10","author":"D Croteau","year":"2021","unstructured":"Croteau D, et al. Effects of Sodium-glucose linked transporter 2 inhibition with ertugliflozin on mitochondrial function, energetics, and metabolic gene expression in the Presence and absence of diabetes Mellitus in mice. J Am Heart Assoc. 2021;10:e019995. https:\/\/doi.org\/10.1161\/JAHA.120.019995.","journal-title":"J Am Heart Assoc"},{"key":"2539_CR84","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1159\/000499597","volume":"49","author":"TC Woods","year":"2019","unstructured":"Woods TC, et al. Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and mitigates kidney Injury and Hypertension in Mouse Model of type 2 diabetes Mellitus. Am J Nephrol. 2019;49:331\u201342. https:\/\/doi.org\/10.1159\/000499597.","journal-title":"Am J Nephrol"},{"key":"2539_CR85","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/jdi.12802","volume":"9","author":"S Takagi","year":"2018","unstructured":"Takagi S, et al. Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. J Diabetes Investig. 2018;9:1025\u201332. https:\/\/doi.org\/10.1111\/jdi.12802.","journal-title":"J Diabetes Investig"},{"key":"2539_CR86","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1093\/eurheartj\/ehab420","volume":"42","author":"H Kondo","year":"2021","unstructured":"Kondo H, et al. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021;42:4947\u201360. https:\/\/doi.org\/10.1093\/eurheartj\/ehab420.","journal-title":"Eur Heart J"},{"key":"2539_CR87","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fphys.2019.00037","volume":"10","author":"D Cuevas-Ramos","year":"2019","unstructured":"Cuevas-Ramos D, Mehta R, Aguilar-Salinas CA. Fibroblast growth factor 21 and Browning of White Adipose tissue. Front Physiol. 2019;10:37. https:\/\/doi.org\/10.3389\/fphys.2019.00037.","journal-title":"Front Physiol"},{"key":"2539_CR88","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02273-3","author":"A Di Vincenzo","year":"2024","unstructured":"Di Vincenzo A, et al. Treatment with dapagliflozin increases FGF-21 gene expression and reduces triglycerides content in myocardial tissue of genetically obese mice. J Endocrinol Invest. 2024. https:\/\/doi.org\/10.1007\/s40618-023-02273-3.","journal-title":"J Endocrinol Invest"},{"key":"2539_CR89","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40360-024-00747-5","volume":"25","author":"L Xiang","year":"2024","unstructured":"Xiang L, et al. Dapagliflozin promotes white adipose tissue browning though regulating angiogenesis in high fat induced obese mice. BMC Pharmacol Toxicol. 2024;25:26. https:\/\/doi.org\/10.1186\/s40360-024-00747-5.","journal-title":"BMC Pharmacol Toxicol"},{"key":"2539_CR90","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1111\/dom.13814","volume":"21","author":"A Giaccari","year":"2019","unstructured":"Giaccari A. Sodium-glucose co-transporter inhibitors: medications that mimic fasting for cardiovascular prevention. Diabetes Obes Metab. 2019;21:2211\u20138. https:\/\/doi.org\/10.1111\/dom.13814.","journal-title":"Diabetes Obes Metab"},{"key":"2539_CR91","doi-asserted-by":"publisher","first-page":"100176","DOI":"10.1016\/j.jlr.2022.100176","volume":"63","author":"K Wallenius","year":"2022","unstructured":"Wallenius K, et al. The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic beta-oxidation, and induces ketosis. J Lipid Res. 2022;63:100176. https:\/\/doi.org\/10.1016\/j.jlr.2022.100176.","journal-title":"J Lipid Res"},{"key":"2539_CR92","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/cvr\/cvx186","volume":"114","author":"E Diaz-Rodriguez","year":"2018","unstructured":"Diaz-Rodriguez E, et al. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. Cardiovasc Res. 2018;114:336\u201346. https:\/\/doi.org\/10.1093\/cvr\/cvx186.","journal-title":"Cardiovasc Res"},{"key":"2539_CR93","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1210\/jc.2014-3472","volume":"100","author":"A Merovci","year":"2015","unstructured":"Merovci A, et al. Dapagliflozin lowers plasma glucose concentration and improves beta-cell function. J Clin Endocrinol Metab. 2015;100:1927\u201332. https:\/\/doi.org\/10.1210\/jc.2014-3472.","journal-title":"J Clin Endocrinol Metab"},{"key":"2539_CR94","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1111\/dom.15586","volume":"26","author":"L Buttice","year":"2024","unstructured":"Buttice L, et al. The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024;26:2706\u201321. https:\/\/doi.org\/10.1111\/dom.15586.","journal-title":"Diabetes Obes Metab"},{"key":"2539_CR95","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13098-023-01085-y","volume":"15","author":"X Wang","year":"2023","unstructured":"Wang X, Wu N, Sun C, Jin D, Lu H. Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2023;15:113. https:\/\/doi.org\/10.1186\/s13098-023-01085-y.","journal-title":"Diabetol Metab Syndr"},{"key":"2539_CR96","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s13340-016-0302-y","volume":"8","author":"Y Bando","year":"2017","unstructured":"Bando Y, et al. The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus. Diabetol Int. 2017;8:218\u201327. https:\/\/doi.org\/10.1007\/s13340-016-0302-y.","journal-title":"Diabetol Int"},{"key":"2539_CR97","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","volume":"61","author":"JW Eriksson","year":"2018","unstructured":"Eriksson JW, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018;61:1923\u201334. https:\/\/doi.org\/10.1007\/s00125-018-4675-2.","journal-title":"Diabetologia"},{"key":"2539_CR98","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2337\/dc17-0518","volume":"40","author":"D Ito","year":"2017","unstructured":"Ito D, et al. Comparison of Ipragliflozin and Pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a Randomized, 24-Week, Open-Label, active-controlled trial. Diabetes Care. 2017;40:1364\u201372. https:\/\/doi.org\/10.2337\/dc17-0518.","journal-title":"Diabetes Care"},{"key":"2539_CR99","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1111\/dom.13750","volume":"21","author":"M Koshizaka","year":"2019","unstructured":"Koshizaka M, et al. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: a prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study). Diabetes Obes Metab. 2019;21:1990\u20135. https:\/\/doi.org\/10.1111\/dom.13750.","journal-title":"Diabetes Obes Metab"},{"key":"2539_CR100","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2337\/dc18-1569","volume":"42","author":"A Latva-Rasku","year":"2019","unstructured":"Latva-Rasku A, et al. The SGLT2 inhibitor Dapagliflozin reduces Liver Fat but does not affect tissue insulin sensitivity: a Randomized, Double-Blind, placebo-controlled study with 8-Week treatment in type 2 diabetes patients. Diabetes Care. 2019;42:931\u20137. https:\/\/doi.org\/10.2337\/dc18-1569.","journal-title":"Diabetes Care"},{"key":"2539_CR101","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1111\/jdi.12985","volume":"10","author":"H Inoue","year":"2019","unstructured":"Inoue H, et al. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: a randomized clinical trial. J Diabetes Investig. 2019;10:1012\u201321. https:\/\/doi.org\/10.1111\/jdi.12985.","journal-title":"J Diabetes Investig"},{"key":"2539_CR102","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","volume":"63","author":"RJ McCrimmon","year":"2020","unstructured":"McCrimmon RJ, et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020;63:473\u201385. https:\/\/doi.org\/10.1007\/s00125-019-05065-8.","journal-title":"Diabetologia"},{"key":"2539_CR103","doi-asserted-by":"publisher","unstructured":"Han E, Lee YH, Lee BW, Kang ES, Cha BS. Ipragliflozin additively ameliorates non-alcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: a 24-Week randomized controlled trial. J Clin Med. 2020;9. https:\/\/doi.org\/10.3390\/jcm9010259.","DOI":"10.3390\/jcm9010259"},{"key":"2539_CR104","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1093\/eurheartj\/ehaa419","volume":"41","author":"AJM Brown","year":"2020","unstructured":"Brown AJM, et al. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. Eur Heart J. 2020;41:3421\u201332. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa419.","journal-title":"Eur Heart J"},{"key":"2539_CR105","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1111\/jdi.13279","volume":"11","author":"T Kinoshita","year":"2020","unstructured":"Kinoshita T, et al. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study. J Diabetes Investig. 2020;11:1612\u201322. https:\/\/doi.org\/10.1111\/jdi.13279.","journal-title":"J Diabetes Investig"},{"key":"2539_CR106","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12933-021-01237-2","volume":"20","author":"B Gaborit","year":"2021","unstructured":"Gaborit B, et al. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovasc Diabetol. 2021;20:57. https:\/\/doi.org\/10.1186\/s12933-021-01237-2.","journal-title":"Cardiovasc Diabetol"},{"key":"2539_CR107","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of Cardiovascular benefits of Sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5:632\u201344. https:\/\/doi.org\/10.1016\/j.jacbts.2020.02.004.","journal-title":"JACC Basic Transl Sci"},{"key":"2539_CR108","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cvr\/cvae047","volume":"120","author":"A Preda","year":"2024","unstructured":"Preda A, et al. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res. 2024;120:443\u201360. https:\/\/doi.org\/10.1093\/cvr\/cvae047.","journal-title":"Cardiovasc Res"},{"key":"2539_CR109","doi-asserted-by":"publisher","unstructured":"D\u2019Marco L et al. SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence. J Diabetes Res 2021, 9032378 (2021). https:\/\/doi.org\/10.1155\/2021\/9032378","DOI":"10.1155\/2021\/9032378"},{"key":"2539_CR110","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12933-024-02322-y","volume":"23","author":"A Ryk","year":"2024","unstructured":"Ryk A, et al. Cholesin receptor signalling is active in cardiovascular system-associated adipose tissue and correlates with SGLT2i treatment in patients with diabetes. Cardiovasc Diabetol. 2024;23:211. https:\/\/doi.org\/10.1186\/s12933-024-02322-y.","journal-title":"Cardiovasc Diabetol"},{"key":"2539_CR111","doi-asserted-by":"publisher","unstructured":"Masson W, Lavalle-Cobo A, Nogueira JP. Effect of SGLT2-Inhibitors on Epicardial Adipose tissue: a Meta-analysis. Cells. 2021;10. https:\/\/doi.org\/10.3390\/cells10082150.","DOI":"10.3390\/cells10082150"},{"key":"2539_CR112","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/oby.22798","volume":"28","author":"G Iacobellis","year":"2020","unstructured":"Iacobellis G, Gra-Menendez S. Effects of Dapagliflozin on Epicardial Fat Thickness in patients with type 2 diabetes and obesity. Obes (Silver Spring). 2020;28:1068\u201374. https:\/\/doi.org\/10.1002\/oby.22798.","journal-title":"Obes (Silver Spring)"},{"key":"2539_CR113","doi-asserted-by":"publisher","first-page":"108509","DOI":"10.1016\/j.jdiacomp.2023.108509","volume":"37","author":"XT Song","year":"2023","unstructured":"Song XT, Wei YL, Rui YF, Fan L. Echocardiographic evaluation of the effect of dapagliflozin on epicardial adipose tissue and left ventricular systolic function in type 2 diabetes mellitus. J Diabetes Complications. 2023;37:108509. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108509.","journal-title":"J Diabetes Complications"},{"key":"2539_CR114","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.mri.2021.11.004","volume":"86","author":"JA Requena-Ibanez","year":"2022","unstructured":"Requena-Ibanez JA, et al. Not only how much, but also how to, when measuring epicardial adipose tissue. Magn Reson Imaging. 2022;86:149\u201351. https:\/\/doi.org\/10.1016\/j.mri.2021.11.004.","journal-title":"Magn Reson Imaging"},{"key":"2539_CR115","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13098-017-0275-4","volume":"9","author":"S Yagi","year":"2017","unstructured":"Yagi S, et al. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2017;9:78. https:\/\/doi.org\/10.1186\/s13098-017-0275-4.","journal-title":"Diabetol Metab Syndr"},{"key":"2539_CR116","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12933-017-0516-8","volume":"16","author":"R Bouchi","year":"2017","unstructured":"Bouchi R, et al. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol. 2017;16:32. https:\/\/doi.org\/10.1186\/s12933-017-0516-8.","journal-title":"Cardiovasc Diabetol"},{"key":"2539_CR117","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","volume":"17","author":"T Sato","year":"2018","unstructured":"Sato T, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018;17:6. https:\/\/doi.org\/10.1186\/s12933-017-0658-8.","journal-title":"Cardiovasc Diabetol"},{"key":"2539_CR118","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.5551\/jat.48009","volume":"27","author":"T Sato","year":"2020","unstructured":"Sato T, et al. The Effect of Dapagliflozin Treatment on Epicardial Adipose tissue volume and P-Wave indices: an Ad-hoc analysis of the previous Randomized Clinical Trial. J Atheroscler Thromb. 2020;27:1348\u201358. https:\/\/doi.org\/10.5551\/jat.48009.","journal-title":"J Atheroscler Thromb"},{"key":"2539_CR119","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","volume":"9","author":"JA Requena-Ibanez","year":"2021","unstructured":"Requena-Ibanez JA, et al. Mechanistic insights of Empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study. JACC Heart Fail. 2021;9:578\u201389. https:\/\/doi.org\/10.1016\/j.jchf.2021.04.014.","journal-title":"JACC Heart Fail"},{"key":"2539_CR120","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12933-021-01228-3","volume":"20","author":"S Hiruma","year":"2021","unstructured":"Hiruma S, et al. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Cardiovasc Diabetol. 2021;20:32. https:\/\/doi.org\/10.1186\/s12933-021-01228-3.","journal-title":"Cardiovasc Diabetol"},{"key":"2539_CR121","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12933-024-02342-8","volume":"23","author":"J Zhao","year":"2024","unstructured":"Zhao J, et al. Excessive accumulation of epicardial adipose tissue promotes microvascular obstruction formation after myocardial ischemia\/reperfusion through modulating macrophages polarization. Cardiovasc Diabetol. 2024;23:236. https:\/\/doi.org\/10.1186\/s12933-024-02342-8.","journal-title":"Cardiovasc Diabetol"},{"key":"2539_CR122","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/eurjpc\/zwad050","volume":"30","author":"AE Malavazos","year":"2023","unstructured":"Malavazos AE, et al. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies. Eur J Prev Cardiol. 2023;30:680\u201393. https:\/\/doi.org\/10.1093\/eurjpc\/zwad050.","journal-title":"Eur J Prev Cardiol"},{"key":"2539_CR123","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12933-024-02298-9","volume":"23","author":"BJ Kasperova","year":"2024","unstructured":"Kasperova BJ, et al. Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure. Cardiovasc Diabetol. 2024;23:223. https:\/\/doi.org\/10.1186\/s12933-024-02298-9.","journal-title":"Cardiovasc Diabetol"},{"key":"2539_CR124","doi-asserted-by":"publisher","unstructured":"Maliszewska K, Kretowski A. Brown Adipose tissue and its role in insulin and glucose homeostasis. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms22041530.","DOI":"10.3390\/ijms22041530"},{"key":"2539_CR125","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1210\/endrev\/bnad015","volume":"44","author":"KA Brown","year":"2023","unstructured":"Brown KA, Scherer PE. Update on adipose tissue and Cancer. Endocr Rev. 2023;44:961\u201374. https:\/\/doi.org\/10.1210\/endrev\/bnad015.","journal-title":"Endocr Rev"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02539-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02539-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02539-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T14:03:09Z","timestamp":1734616989000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02539-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":125,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2539"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02539-x","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"449"}}